Multiple growth catalysts falling in place for Natco Pharma: Analysts
Strong impetus to exports by a mega product launch in North America and business outside the US bode well for earnings19-10-2020
19-10-2020
NATCO PHARMA LTD. - 524816 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Natco Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here16-10-2020
NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results of 37th Annual General Meeting along with the Scrutinisers Report16-10-2020
Natco Pharma eyes launch of 8-10 new drugs yearly in Indian market
Natco Pharma aims to launch around 10 new products every year in the Indian market, the city-based drug maker said on Thursday15-10-2020
NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome and Proceedings of the 37th Annual General Meeting15-10-2020
NATCO PHARMA LTD. - 524816 - PCS Compliance Certificate For The Period Ended 30Th September,2020
PCS Compliance certificate for the period ended 30th September,202006-10-2020
NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended September 30, 2020
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here06-10-2020
Stock query: Natco Pharma on medium-term uptrend
But the stock faces a significant resistance ahead at 1,00004-10-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S30-09-2020
NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading window remain closed for the Directors, Promoters and Designated persons covered under SEBI (PIT) Regulations, 201530-09-2020